Marksans Pharma Limited announces USFDA approval for Acetaminophen ExtendedRelease Tablets USP, 650 mg (OTC).

Marksans Pharma Limited (Reuters: MARK.BO; Bloomberg: MRKS IN; NSE: MARKSANS; BSE: 524404) hereby announces that USFDA has granted approval for an Abbreviated New Drug Application (ANDA) for Acetaminophen Extended-Release Tablets USP, 650 mg (OTC).

Acetaminophen Extended-Release Tablets are bioequivalent to the reference listed drug, Tylenol Extended-Release Tablets, 650 mg, of Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division.

This product approval endorses the capability of Marksans to develop and deliver products on a high barrier platform technology of extended release tablets. Extended release is an advanced technology and is a solution to patient compliance to avoid repeated dosages at short intervals.

Marksans will manufacture the products at its USFDA approved state-of-the-art solid oral dosage facility located at Goa, India.

Shares of Marksans Pharma Ltd. was last trading in BSE at Rs. 71.65 as compared to the previous close of Rs. 69.85. The total number of shares traded during the day was 450313 in over 2998 trades.

The stock hit an intraday high of Rs. 72.9 and intraday low of 69.2. The net turnover during the day was Rs. 32190926.

Source : Equity Bulls

Keywords